Maintenance immunotherapy after transplant for high-risk Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether adding maintenance immunotherapy (nivolumab or pembrolizumab) after a stem cell transplant improves outcomes compared to the usual care alone for patients with high-risk relapsed or refractory classical Hodgkin lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 5–75 years old and have been diagnosed with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
- You need to have had a PET/CT or MRI within 56 days before entering the study to confirm the relapse.
- You must be considered high-risk, which includes primary refractory disease, relapse within 3–6 months of frontline therapy, having more than 4 disease sites at relapse, or bone marrow involvement.
- You must be eligible for high-dose chemotherapy and an autologous stem cell transplant.
- You need to have adequate organ function, including blood counts and kidney and liver tests within normal ranges.
- You must not be pregnant or breastfeeding, and if you could become pregnant, you must agree to use effective contraception during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests brentuximab and nivolumab (two anti-cancer medicines) in people with classical Hodgkin lymphoma that has come back or did not respond to earlier treatment. It may help by attacking lymphoma cells in different ways, especially after limited options from prior therapies.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This trial tests whether a PD-1 inhibitor (a type of immunotherapy) given after an autologous stem cell transplant can help prevent Hodgkin lymphoma from coming back in people at high risk of relapse.
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
This trial tests a combination of three drugs (chidamide, decitabine, and an immunotherapy drug called an anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has come back or not responded to at least two previous treatments. It may be an option if you cannot have or do not want a stem cell transplant.
Hear when a new Refractory Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.